Cargando…
Efficacy and tolerability of topical sertaconazole versus topical terbinafine in localized dermatophytosis: A randomized, observer-blind, parallel group study
OBJECTIVE: Epidermal dermatophyte infections most commonly manifest as tinea corporis or tinea cruris. Topical azole antifungals are commonly used in their treatment but literature suggests that most require twice-daily application and provide lower cure rates than the allylamine antifungal terbinaf...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5155466/ https://www.ncbi.nlm.nih.gov/pubmed/28066103 http://dx.doi.org/10.4103/0253-7613.194850 |
_version_ | 1782475008699793408 |
---|---|
author | Chatterjee, Dattatreyo Ghosh, Sudip Kumar Sen, Sukanta Sarkar, Saswati Hazra, Avijit De, Radharaman |
author_facet | Chatterjee, Dattatreyo Ghosh, Sudip Kumar Sen, Sukanta Sarkar, Saswati Hazra, Avijit De, Radharaman |
author_sort | Chatterjee, Dattatreyo |
collection | PubMed |
description | OBJECTIVE: Epidermal dermatophyte infections most commonly manifest as tinea corporis or tinea cruris. Topical azole antifungals are commonly used in their treatment but literature suggests that most require twice-daily application and provide lower cure rates than the allylamine antifungal terbinafine. We conducted a head-to-head comparison of the effectiveness of the once-daily topical azole, sertaconazole, with terbinafine in these infections. MATERIALS AND METHODS: We conducted a randomized, observer-blind, parallel group study (Clinical Trial Registry India [CTRI]/2014/09/005029) with adult patients of either sex presenting with localized lesions. The clinical diagnosis was confirmed by potassium hydroxide smear microscopy of skin scrapings. After baseline assessment of erythema, scaling, and pruritus, patients applied either of the two study drugs once daily for 2 weeks. If clinical cure was not seen at 2 weeks, but improvement was noted, application was continued for further 2 weeks. Patients deemed to be clinical failure at 2 weeks were switched to oral antifungals. RESULTS: Overall 88 patients on sertaconazole and 91 on terbinafine were analyzed. At 2 weeks, the clinical cure rates were comparable at 77.27% (95% confidence interval [CI]: 68.52%–86.03%) for sertaconazole and 73.63% (95% CI 64.57%–82.68%) for terbinafine (P = 0.606). Fourteen patients in either group improved and on further treatment showed complete healing by another 2 weeks. The final cure rate at 4 weeks was also comparable at 93.18% (95% CI 88.75%–97.62%) and 89.01% (95% CI 82.59%–95.44%), respectively (P = 0.914). At 2 weeks, 6 (6.82%) sertaconazole and 10 (10.99%) terbinafine recipients were considered as “clinical failure.” Tolerability of both preparations was excellent. CONCLUSION: Despite the limitations of an observer-blind study without microbiological support, the results suggest that once-daily topical sertaconazole is as effective as terbinafine in localized tinea infections. |
format | Online Article Text |
id | pubmed-5155466 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-51554662017-01-06 Efficacy and tolerability of topical sertaconazole versus topical terbinafine in localized dermatophytosis: A randomized, observer-blind, parallel group study Chatterjee, Dattatreyo Ghosh, Sudip Kumar Sen, Sukanta Sarkar, Saswati Hazra, Avijit De, Radharaman Indian J Pharmacol Research Article OBJECTIVE: Epidermal dermatophyte infections most commonly manifest as tinea corporis or tinea cruris. Topical azole antifungals are commonly used in their treatment but literature suggests that most require twice-daily application and provide lower cure rates than the allylamine antifungal terbinafine. We conducted a head-to-head comparison of the effectiveness of the once-daily topical azole, sertaconazole, with terbinafine in these infections. MATERIALS AND METHODS: We conducted a randomized, observer-blind, parallel group study (Clinical Trial Registry India [CTRI]/2014/09/005029) with adult patients of either sex presenting with localized lesions. The clinical diagnosis was confirmed by potassium hydroxide smear microscopy of skin scrapings. After baseline assessment of erythema, scaling, and pruritus, patients applied either of the two study drugs once daily for 2 weeks. If clinical cure was not seen at 2 weeks, but improvement was noted, application was continued for further 2 weeks. Patients deemed to be clinical failure at 2 weeks were switched to oral antifungals. RESULTS: Overall 88 patients on sertaconazole and 91 on terbinafine were analyzed. At 2 weeks, the clinical cure rates were comparable at 77.27% (95% confidence interval [CI]: 68.52%–86.03%) for sertaconazole and 73.63% (95% CI 64.57%–82.68%) for terbinafine (P = 0.606). Fourteen patients in either group improved and on further treatment showed complete healing by another 2 weeks. The final cure rate at 4 weeks was also comparable at 93.18% (95% CI 88.75%–97.62%) and 89.01% (95% CI 82.59%–95.44%), respectively (P = 0.914). At 2 weeks, 6 (6.82%) sertaconazole and 10 (10.99%) terbinafine recipients were considered as “clinical failure.” Tolerability of both preparations was excellent. CONCLUSION: Despite the limitations of an observer-blind study without microbiological support, the results suggest that once-daily topical sertaconazole is as effective as terbinafine in localized tinea infections. Medknow Publications & Media Pvt Ltd 2016 /pmc/articles/PMC5155466/ /pubmed/28066103 http://dx.doi.org/10.4103/0253-7613.194850 Text en Copyright: © Indian Journal of Pharmacology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Research Article Chatterjee, Dattatreyo Ghosh, Sudip Kumar Sen, Sukanta Sarkar, Saswati Hazra, Avijit De, Radharaman Efficacy and tolerability of topical sertaconazole versus topical terbinafine in localized dermatophytosis: A randomized, observer-blind, parallel group study |
title | Efficacy and tolerability of topical sertaconazole versus topical terbinafine in localized dermatophytosis: A randomized, observer-blind, parallel group study |
title_full | Efficacy and tolerability of topical sertaconazole versus topical terbinafine in localized dermatophytosis: A randomized, observer-blind, parallel group study |
title_fullStr | Efficacy and tolerability of topical sertaconazole versus topical terbinafine in localized dermatophytosis: A randomized, observer-blind, parallel group study |
title_full_unstemmed | Efficacy and tolerability of topical sertaconazole versus topical terbinafine in localized dermatophytosis: A randomized, observer-blind, parallel group study |
title_short | Efficacy and tolerability of topical sertaconazole versus topical terbinafine in localized dermatophytosis: A randomized, observer-blind, parallel group study |
title_sort | efficacy and tolerability of topical sertaconazole versus topical terbinafine in localized dermatophytosis: a randomized, observer-blind, parallel group study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5155466/ https://www.ncbi.nlm.nih.gov/pubmed/28066103 http://dx.doi.org/10.4103/0253-7613.194850 |
work_keys_str_mv | AT chatterjeedattatreyo efficacyandtolerabilityoftopicalsertaconazoleversustopicalterbinafineinlocalizeddermatophytosisarandomizedobserverblindparallelgroupstudy AT ghoshsudipkumar efficacyandtolerabilityoftopicalsertaconazoleversustopicalterbinafineinlocalizeddermatophytosisarandomizedobserverblindparallelgroupstudy AT sensukanta efficacyandtolerabilityoftopicalsertaconazoleversustopicalterbinafineinlocalizeddermatophytosisarandomizedobserverblindparallelgroupstudy AT sarkarsaswati efficacyandtolerabilityoftopicalsertaconazoleversustopicalterbinafineinlocalizeddermatophytosisarandomizedobserverblindparallelgroupstudy AT hazraavijit efficacyandtolerabilityoftopicalsertaconazoleversustopicalterbinafineinlocalizeddermatophytosisarandomizedobserverblindparallelgroupstudy AT deradharaman efficacyandtolerabilityoftopicalsertaconazoleversustopicalterbinafineinlocalizeddermatophytosisarandomizedobserverblindparallelgroupstudy |